TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FETROJA

CEFIDEROCOL SULFATE TOSYLATE
Infectious Disease Approved 2019-11-14
2
Indications
--
Phase 3 Trials
2
Priority Reviews
6
Years on Market

Details

Status
Prescription
First Approved
2019-11-14
Routes
INTRAVENOUS
Dosage Forms
POWDER

Companies

Active Ingredient: CEFIDEROCOL SULFATE TOSYLATE

FETROJA Approval History

Loading approval history...

What FETROJA Treats

4 indications

FETROJA is approved for 4 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Complicated Urinary Tract Infection
  • Pyelonephritis
  • Hospital-Acquired Pneumonia
  • Ventilator-Associated Pneumonia
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FETROJA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria....

FETROJA Patents & Exclusivity

Latest Patent: Sep 2035
Exclusivity: Nov 2029

Patents (5 active)

US10004750 Expires Sep 3, 2035
US9949982 Expires Sep 3, 2035
US9238657 Expires Nov 14, 2033

Exclusivity

NCE Until Nov 2024
GAIN Until Nov 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.